312 related articles for article (PubMed ID: 15908955)
1. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors.
Idris AI; van 't Hof RJ; Greig IR; Ridge SA; Baker D; Ross RA; Ralston SH
Nat Med; 2005 Jul; 11(7):774-9. PubMed ID: 15908955
[TBL] [Abstract][Full Text] [Related]
2. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor.
Idris AI; Sophocleous A; Landao-Bassonga E; van't Hof RJ; Ralston SH
Endocrinology; 2008 Nov; 149(11):5619-26. PubMed ID: 18635663
[TBL] [Abstract][Full Text] [Related]
3. Combined deficiency of the Cnr1 and Cnr2 receptors protects against age-related bone loss by osteoclast inhibition.
Sophocleous A; Marino S; Kabir D; Ralston SH; Idris AI
Aging Cell; 2017 Oct; 16(5):1051-1061. PubMed ID: 28752643
[TBL] [Abstract][Full Text] [Related]
4. Peripheral cannabinoid receptor, CB2, regulates bone mass.
Ofek O; Karsak M; Leclerc N; Fogel M; Frenkel B; Wright K; Tam J; Attar-Namdar M; Kram V; Shohami E; Mechoulam R; Zimmer A; Bab I
Proc Natl Acad Sci U S A; 2006 Jan; 103(3):696-701. PubMed ID: 16407142
[TBL] [Abstract][Full Text] [Related]
5. The genetic ablation or pharmacological inhibition of TRPV1 signalling is beneficial for the restoration of quiescent osteoclast activity in ovariectomized mice.
Rossi F; Bellini G; Torella M; Tortora C; Manzo I; Giordano C; Guida F; Luongo L; Papale F; Rosso F; Nobili B; Maione S
Br J Pharmacol; 2014 May; 171(10):2621-30. PubMed ID: 24308803
[TBL] [Abstract][Full Text] [Related]
6. Critical role of beta3 integrin in experimental postmenopausal osteoporosis.
Zhao H; Kitaura H; Sands MS; Ross FP; Teitelbaum SL; Novack DV
J Bone Miner Res; 2005 Dec; 20(12):2116-23. PubMed ID: 16294265
[TBL] [Abstract][Full Text] [Related]
7. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.
Tham M; Yilmaz O; Alaverdashvili M; Kelly MEM; Denovan-Wright EM; Laprairie RB
Br J Pharmacol; 2019 May; 176(10):1455-1469. PubMed ID: 29981240
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro.
Whyte LS; Ford L; Ridge SA; Cameron GA; Rogers MJ; Ross RA
Br J Pharmacol; 2012 Apr; 165(8):2584-97. PubMed ID: 21649637
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid CB
Weresa J; Pędzińska-Betiuk A; Kossakowski R; Malinowska B
Pharmacol Rep; 2019 Feb; 71(1):82-89. PubMed ID: 30500553
[TBL] [Abstract][Full Text] [Related]
10. [The endocannabinoid system and bone].
Pura M; Vaňuga P
Vnitr Lek; 2016; 62(9 Suppl 3):99-102. PubMed ID: 27734700
[TBL] [Abstract][Full Text] [Related]
11. The endovanilloid/endocannabinoid system: a new potential target for osteoporosis therapy.
Rossi F; Bellini G; Luongo L; Torella M; Mancusi S; De Petrocellis L; Petrosino S; Siniscalco D; Orlando P; Scafuro M; Colacurci N; Perrotta S; Nobili B; Di Marzo V; Maione S;
Bone; 2011 May; 48(5):997-1007. PubMed ID: 21237298
[TBL] [Abstract][Full Text] [Related]
12. alpha-Lipoic acid inhibits inflammatory bone resorption by suppressing prostaglandin E2 synthesis.
Ha H; Lee JH; Kim HN; Kim HM; Kwak HB; Lee S; Kim HH; Lee ZH
J Immunol; 2006 Jan; 176(1):111-7. PubMed ID: 16365401
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors.
Reggio PH
Curr Pharm Des; 2003; 9(20):1607-33. PubMed ID: 12871061
[TBL] [Abstract][Full Text] [Related]
14. A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss.
Aoki K; Saito H; Itzstein C; Ishiguro M; Shibata T; Blanque R; Mian AH; Takahashi M; Suzuki Y; Yoshimatsu M; Yamaguchi A; Deprez P; Mollat P; Murali R; Ohya K; Horne WC; Baron R
J Clin Invest; 2006 Jun; 116(6):1525-34. PubMed ID: 16680194
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid Receptor 2 Agonist Prevents Local and Systemic Inflammatory Bone Destruction in Rheumatoid Arthritis.
Zhu M; Yu B; Bai J; Wang X; Guo X; Liu Y; Lin J; Hu S; Zhang W; Tao Y; Hu C; Yang H; Xu Y; Geng D
J Bone Miner Res; 2019 Apr; 34(4):739-751. PubMed ID: 30508319
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of COX-2-mediated eicosanoid production plays a major role in the anti-inflammatory effects of the endocannabinoid N-docosahexaenoylethanolamine (DHEA) in macrophages.
Meijerink J; Poland M; Balvers MG; Plastina P; Lute C; Dwarkasing J; van Norren K; Witkamp RF
Br J Pharmacol; 2015 Jan; 172(1):24-37. PubMed ID: 24780080
[TBL] [Abstract][Full Text] [Related]
17. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow.
Shibata T; Shira-Ishi A; Sato T; Masaki T; Masuda A; Hishiya A; Ishikura N; Higashi S; Uchida Y; Saito MO; Ito M; Ogata E; Watanabe K; Ikeda K
J Bone Miner Res; 2002 Apr; 17(4):622-9. PubMed ID: 11918219
[TBL] [Abstract][Full Text] [Related]
19. Differential modulation of endogenous cannabinoid CB1 and CB2 receptors in spontaneous and splice variants of ghrelin-induced food intake in conscious rats.
Ting CH; Chi CW; Li CP; Chen CY
Nutrition; 2015 Jan; 31(1):230-5. PubMed ID: 25466669
[TBL] [Abstract][Full Text] [Related]
20. PKCβII-mediated cross-talk of TRPV1/CB2 modulates the glucocorticoid-induced osteoclast overactivity.
Bellini G; Torella M; Manzo I; Tortora C; Luongo L; Punzo F; Colacurci N; Nobili B; Maione S; Rossi F
Pharmacol Res; 2017 Jan; 115():267-274. PubMed ID: 27919827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
